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SUMMARY
Epilepsy is a common, debilitating neurological disorder characterized by recurrent
seizures. Mood disorders and cognitive deficits are common comorbidities in epilepsy
that, like seizures, profoundly influence quality of life and can be difficult to treat. For
patients with refractory epilepsy who are not candidates for resection, neurostimula-
tion, the electrical modulation of epileptogenic brain tissue, is an emerging treatment
alternative. Several forms of neurostimulation are currently available, and therapy
selection hinges on relative efficacy for seizure control and amelioration of neuropsy-
chiatric comorbidities. Here, we review the current evidence for how invasive and non-
invasive neurostimulation therapies affect mood and cognition in persons with
epilepsy. Invasive therapies include vagus nerve stimulation (VNS), deep brain stimula-
tion (DBS), and responsive neurostimulation (RNS). Noninvasive therapies include
trigeminal nerve stimulation (TNS), repetitive transcranial magnetic stimulation
(rTMS), and transcranial direct current stimulation (tDCS). Overall, current evidence
supports stable cognition and mood with all neurostimulation therapies, although
there is some evidence that cognition and mood may improve with invasive forms of
neurostimulation. More research is required to optimize the effects of neurostimula-
tion for improvements in cognition andmood.
KEY WORDS: Vagus nerve stimulation, Deep brain stimulation, Responsive neu-
rostimulation, Trigeminal nerve stimulation, Repetitive transcranial magnetic stimu-
lation, Transcranial direct current stimulation, Epilepsy surgery.
Epilepsy—the enduring tendency for recurrent, unpro-
voked seizures—is a debilitating disorder that affects mil-
lions of patients worldwide.1,2 Despite the availability of
more than 20 anticonvulsant medications, seizures are
incompletely controlled by medication in a third of cases.3–5
If seizures are well-localized in the brain, resection of the
epileptogenic focus can result in high rates of seizure free-
dom.6,7 However, some patients are not candidates for
resection, typically because they have multiple seizure foci
or a focus co-localizing with eloquent cortex. For these
patients, an alternative treatment is neurostimulation, which
includes vagus nerve stimulation (VNS), deep brain stimu-
lation (DBS), and responsive neurostimulation (RNS), as
well as recent, less-invasive therapies including trigeminal
nerve stimulation (TNS), transcranial direct current stimula-
tion (tDCS), and transcranial magnetic stimulation (TMS).
These therapies vary in their efficacy for seizure reduction8
and are associated with different side-effect profiles.9
Of increasing interest is how these neurostimulation ther-
apies affect mood and cognition (egg, memory, attention,
language, and executive function) because both are well-
recognized comorbidities of epilepsy. Depression may be a
stronger predictor of quality of life than seizure frequency
in patients with in epilepsy.10,11 Here, we summarize the
current evidence on the effects of neurostimulation on
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cognition and mood, and how it should be used to guide
treatment strategy to optimize patient outcomes.
Methods
Three separate queries of PubMed were made to find rele-
vant articles. Searches were restricted to English-language
studies with human subjects. The search terms were the fol-
lowing: “epilepsy,” with “cognition,” or “mood,” and “va-
gus nerve stimulation,” “RNS,” or “deep brain stimulation.”
This led to 6 separate queries in total (eg, “epilepsy cogni-
tion vagus nerve stimulation,” “epilepsy mood vagus nerve
stimulation,” and so on) The references of relevant studies
and reviews were evaluated for additional articles. Studies
were included for the following reasons: (1) the article was
peer-reviewed; (2) there was a form of neuromodulation
intervention; (3) original data on either cognition or mood
were presented; (4) the primary indication for neuromodula-
tion was intractable epilepsy; and (5) the sample size was
larger than 5 patients or subjects to minimize potential pub-
lication bias. Studies were excluded if they were determined
to have overlapping patients from other studies or were
meeting abstracts only.
Level of evidence was determined based on past recom-
mendations.12 Level 1 evidence was considered either a ran-
domized, controlled trial or a properly controlled
experimental study. Level 2 consisted of experimental stud-
ies with fewer than 20 subjects, prospective observational or
case-control studies. Level 3 evidence was provided by ret-
rospective studies.
Results
Queries for studies investigating cognition returned 46,
28, and 3 for vagus nerve stimulation, deep brain stimula-
tion, and responsive neurostimulation (or RNS), respec-
tively. The queries for mood returned 88, 22, 4 for vagus
nerve stimulation, deep brain stimulation, and responsive
neurostimulation (or RNS), respectively. The included stud-
ies are summarized in Tables 2 and 3.
Discussion
Vagus nerve stimulation
VNS is a widely used and well-investigated form of neu-
rostimulation for epilepsy. A coil electrode is positioned
around the left vagus nerve in the neck and connected to a
pulse generator implanted in the chest. The precise mecha-
nism of action is unclear. One hypothesis is that VNS sends
antidromic pulses to the brainstem nucleus of the solitary
tract and nucleus locus coeruleus, which in turn activate
noradrenergic neurons that project diffusely in the brain to
reduce seizure frequency, cortical spread, and duration.13
The results of a double-blinded randomized study (EO5)
consisting of 195 patients described median seizure reduc-
tion of 45% at 1 year, with 35% of patients being responders
(ie, over 50% seizure reduction) and 20% having a seizure
reduction of over 75% (Table 1).14
Like other forms of neurostimulation, VNS tends to have
progressively increasing efficacy, meaning that longer dura-
tion of treatment correlates with better seizure control. For
example, a study of 28 patients reported a change from a
median 28% seizure reduction at 1 year to 72% reduction at
last follow-up, which was 5–7 years.15 Common side
effects are typically minor and include throat irritation,
cough, dysphonia, and sleep disruption.16,17
VNS effects on cognition
The overall effect of VNS on cognition is unclear, and
much of the investigation has focused on memory. How-
ever, there is some evidence that VNS increases cognitive
functioning, at least in the short term (Table 2). Clark
et al.18 showed that when patients read unfamiliar, emotion-
ally neutral paragraphs, they were more likely to retain
tested, highlighted words if they were stimulated with 30 s
of 0.50 mA pulses after reading the text. The authors con-
cluded that VNS enhanced word retention and thus short-
term memory. Important study limitations were the sample
size (only 10 patients) and that the results were relatively
short term.
Another study of 20 subjects investigating the effects of
VNS on attention, cognition, and emotional reactivity found
that subjects had improved working memory performance
with VNS.19More specifically, patients were presented with
a triangle pointed upward or downward and had to recall its
orientation when prompted by a visual cue. Patients had sig-
nificantly reduced recall errors when cyclic VNS was on
than when it was off (odds ratio [OR] 0.63). In contrast,
Helmstaedter et al.20 tested verbal and figural recognition
~10 months after VNS implantation and found that stimula-
tion negatively affected aspects of cognition. In their study,
11 patients were subjected to high-intensity VNS (over
1 mA) during and immediately following verbal and figural
Key Points
• Mood disorders and cognitive deficits are common
comorbidities in epilepsy that profoundly influence
quality of life
• Several forms of neurostimulation are available, and
selection hinges on seizure control and amelioration
of neuropsychiatric comorbidities
• We review the evidence for how invasive and nonin-
vasive neurostimulation therapies affect mood and
cognition in persons with epilepsy
• Overall, current evidence supports stable cognition
and mood with all neurostimulation therapies, but
more research is necessary
Epilepsia Open, 3(1):18–29, 2018
doi: 10.1002/epi4.12100
19
Cognition andMood in Neurostimulation
recognition tasks. The subjects were initially exposed to
novel word lists and figures before being tested on recogni-
tion. The subjects performed significantly worse during fig-
ure recognition with VNS stimulation than without it,
whereas performance was unchanged in verbal recognition.
The authors suggest that their results and conclusions dif-
fered from those of Clark et al.18 because (1) the patients
were stimulated during learning as well as immediate recog-
nition, whereas Clark et al. only delivered stimulation dur-
ing retention intervals, and (2) the stimulation was stronger
in their experiment compared to Clark et al. (>1 mA vs
0.5 mA). Limitations of this study include a small sample
size (n = 11) and the fact that the control group was
described as healthy, implying that they were not patients
with pharmacoresistant epilepsy.
Longer-term studies have generally shown that VNS has
no significant effect on memory.21 A randomized, con-
trolled study of 160 patients investigated the long-term cog-
nitive effects by testing patients prior to implantation and
then 3-4 months postoperatively.22 One group of patients
was assigned to minimal VNS stimulation, whereas another
was assigned to the clinically used stimulation intensity.
There was no significant difference between the 2 groups
for any of the testing metrics, and the authors concluded that
there were no cognitive changes. In another study of 40
patients investigating the long-term effects of VNS on cog-
nition, patients were scored immediately before and
6 months after VNS implantation using abstract reasoning
multiple choice tests.23 There was no significant difference
between the exams, suggesting that VNS has no long-term
effects on cognition, at least for that domain. Smaller studies
with longer testing intervals (eg, 12 months) have shown
similar results.24,25
The positive cognitive effects from VNS, if they exist,
are likely seen beyond 1-year postimplantation. Data in
pediatric patients suggest that VNS may have positive
effects on aspects of cognition outside of memory. Orosz
et al26 investigated the effects of VNS on 347 pediatric
patients, assessing different qualities like alertness, con-
centration, memory, verbal communication, and progres-
sion with school work, as well as frequency of seizure
reduction at 12 and 24 months. The results showed that a
relatively high proportion of patients substantially
improved in concentration, verbal communication, and
progress in school work between 12 and 24 months, with
about half of patients showing no improvement in mem-
ory. Specifically, the number of patients who were “better
or much better than before VNS” in concentration were
85/200 (42.5%) and 60/109 (55.0%) at 12 and 24 months,
respectively, 57/200 (28.5%) and 45/109 (41.3%) at 12
and 24 months for verbal communication, and 62/200
(31%) and 37/109 (33.9%) at 12 and 24 months for pro-
gress with schoolwork. This suggests that VNS could
have a positive effect on long-term cognition but that the
benefit may not be realized until after 12 months. A limi-
tation of this study was that there seemed to be patients
lost to follow-up at 12 and 24 months, which allowed for
potential selection bias. Furthermore, an analysis of provi-
der survey data of 5,000 patients, including 3,000 with
over 1-year follow-up, showed that patients had improve-
ments in alertness, verbal communication, and memory.27
The authors note that their data could have been skewed
toward more favorable outcomes because physicians have
a natural desire to see improvement in their patients;
therefore the results must be interpreted within that con-
text. Another limitation is that these studies are retrospec-
tive and thus cannot control for reduction in seizure
frequency as a potential confounding factor. Taken
together, the literature does not support cognitive impair-
ment with chronic VNS and there are limited data to sug-
gest that it may enhance cognition in certain areas,
particularly over long periods.
VNS effect on mood
The use of VNS in patients with refractory epilepsy has
generally shown an improvement of mood (Table 3). VNS
has been explored as a treatment for a number of psychiatric
disorders (eg, depression, obsessive compulsive disorder,
and mood disorders).28 In particular, VNS has been shown
to be effective in patients with treatment-resistant depres-
sion (TRD), as assessed by the Inventory of Depressive
Symptomatology-Clinician Administered Version (IDS-
C),29 and TRD is an US Food and Drug Administration
(FDA)–approved indication for VNS. However, the positive
Table 1. Responder rate frequency (ie, percentage of patients with ≥50% seizure reduction) for invasive
neurostimulation from open-label randomized controlled trials
Vagus nerve stimulation Deep brain stimulation Responsive neurostimulation
1-Year seizure reduction 45% (n = 195) 41% (n = 99) 44% (n = 182)
1-Year responder rate 34% (n = 195) 43% (n = 105) 44% (n = 182)
2-Year seizure reduction 47% (n = 188) 56% (n = 82) 53% (n = 175)
2-Year responder rate 43% (n = unclear) N/A 55% (n = 175)
5-Year seizure reduction 64% (n = 90)* 69% (n = 59) 66% (n = 172)
5-Year responder rate 64% (n = 90)* 68% (n = 83) 61% (n = 172)
Declining number data were used when available. Medians are provided unless otherwise specified. 13,36,49,66,67
*From retrospective, open-label study (Kuba et al 2009).68
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effect of VNS on mood in patients with refractory epilepsy
is less clear. A study that analyzed self-report questionnaires
from 28 VNS patients with refractory epilepsy found that,
although VNS made patients less tense and dysphoric (as
measured with by 2 self-reported scales designed to assess
anxiety and dysphoria), there were no improvements in any
metrics of depression as measured by the Beck Depression
Inventory, a self-reported questionnaire.30 A larger study of
112 patients undergoing VNS therapy found improvement
in quality of life but no significant improvement in metrics
that measure depression.31 Conversely, Klinkenberg et al23
reported a prospective longitudinal observational cohort
study of 41 patients with refractory epilepsy treated with
VNS, and found that patients had lower levels of anxiety,
tension, and depression at 6-month follow-up. A number of
smaller studies also found that VNS was associated with
reduction in depressive symptoms.32,33 Overall, the current
evidence is mixed but generally supports a positive effect of
VNS on mood.
Deep brain stimulation
DBS was originally shown to be effective in movement
disorders, like Parkinson’s disease and essential tremor, and
it has since been utilized in other neurological disorders,
including refractory epilepsy.34 Although the exact mecha-
nism of action for treating seizures is unclear, it is thought
that electrical stimulation of key brain regions creates a
pseudo-lesion that disrupts seizure propagation.34 Targets
of stimulation include the centromedian and anterior nuclei
of the thalamus, due to their roles in cortical activation and
the circuit of Papez, respectively. Velasco et al.35 investi-
gated the effect of stimulating the centromedian nucleus for
treating generalized seizures in 13 patients with Lennox-
Gastaut syndrome and found that the overall seizure reduc-
tion was 80% at 18 months. Similarly, Son et al36 found
that centromedian thalamic nuclei stimulation effectively
reduced seizures in 11 of 14 patients, including 100% of
those with Lennox-Gastaut syndrome.
Recently, the anterior thalamic nucleus (ATN) has
emerged as a promising target for DBS in epilepsy. Sala-
nova et al.37 reported the results of the Stimulation of the
Anterior Nucleus of the Thalamus for Epilepsy (SANTE)
study, a prospective randomized blinded trial of 110 patients
treated with bilateral ATN stimulation. Median seizure fre-
quency reduction for ATN DBS was 41% and 69% at 1 and
5 years, respectively, whereas the responder rate (percent of
patients with at least 50% seizure reduction compared to
baseline) was 43% and 58% at 1 and 5 years, respectively
(Table 1). Potential limitations of DBS of the ATN pertain
to patient subjective reports of memory problems and
depression, although there is no evidence of objective, long-
term neurobehavioral worsening.38 There is evidence of
sleep disruption related to thalamic stimulation,39 which
could conceivably explain memory and mood symptoms.
Other complications reported in the SANTE trial included
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pain associated with the procedure, implant site infection,
and misplaced leads.
DBS effects on cognition
Much of the data on the cognitive effects of DBS come
from studies of patients undergoing ATN stimulation
(Table 2). DBS may be effective in treating disorders of
memory and cognition, like Alzheimer’s and Parkinson’s
disease,40 and so DBS for epilepsy may be associated with
cognitive benefits as well.
There is relatively recent evidence that DBS of the medial
temporal lobe in various neurological disorders has the
potential to enhance learning and memory.41 The ATN is
intricately involved in learning and memory, and it may also
play a role in executive function.42 Thus it would seem intu-
itive that any effect of stimulation on the ATN would effect
cognition, specifically memory. Results from a small study
of 9 patients with at least 1-year follow-up showed that cog-
nitive testing improved significantly after DBS of the ATN
in verbal fluency tasks and delayed verbal memory.43
Specifically, patients improved in their “category” and “let-
ter” word fluency tasks as well as on delayed verbal recall
tasks; moreover, none of the patients showed any significant
declines in the cognitive metrics used.
There was concern for memory and cognitive decline
with long-term treatment with ATN DBS. New-onset mem-
ory problems were endorsed by almost 30% of patients in
the SANTE trial, although 50% of them had memory
impairment at baseline.37 However, objective metrics from
the SANTE trial showed that patients had significant
improvements in attention and executive function without
significant declines in verbal or visual memory at 5 years.
A later study reanalyzed the data from the SANTE trial to
investigate the complaints of memory deficits and depres-
sion and found that these patients did not have any objective
cognitive declines through the blinded or open-label
phases.38 Moreover, the patients actually improved signifi-
cantly in some tested components of executive function,
visual spatial memory, and attention. Executive function
and visual attention were tested via the Delis-Kaplan Execu-
tive Function System (D-KEFS), whereas visual spatial
memory was tested via the Brief Visual Memory Test-
Revised. The mean scores for 3 of 4 metrics testing execu-
tive functioning in D-KEFS improved significantly roughly
15%-40% between baseline and follow-up. Two mean
scores for visual attention metrics improved approximately
20% in that time, and the mean for 1 visual spatial metric
improved about 8%. There were important limitations of
this study that should be considered. First, although there
were no negative cognitive effects, there was no long-term
control group with which to compare results. Therefore, the
authors argue that patients should still be monitored for
changes in cognition. Second, the authors retrospectively
analyzed previously collected data (ie, post hoc analysis),
which could have influenced their results.
DBS effect on mood
Like VNS, DBS has been used to treat psychiatric ill-
nesses such as TRD and thus may have potential for improv-
ing mood in patients with epilepsy. In TRD, stimulation
targets include subcallosal cingulate44 or nucleus accum-
bens.45 There is evidence though that DBS also positively
affects mood in patients with epilepsy. Objective data from
the SANTE trial showed that DBS on the ATN likely ele-
vates mood as well as decreases seizure frequency.37 At
5 years after implantation, patients had significant improve-
ments in depression, tension/anxiety, and total mood distur-
bances when compared to baseline. Further analysis showed
that Profile of Mood State (POMS) test scores for depres-
sion or apathy did not change significantly between baseline
prior to implantation and 7 years postoperatively
(Table 3).38 The limitation of the current evidence is that
the strongest data all come from the same study (ie, SANTE
trial), which creates the need for additional investigation.
Responsive neurostimulation
In contrast to VNS and DBS, which deliver “open-loop”
(ie, scheduled intermittent or continuous) electrical stimula-
tion to their targets, RNS is a “closed-loop” therapy that
involves delivery of electrical stimulation directly to the sei-
zure focus only in response to detection of abnormal pattern
of neural activity.46 RNS is indicated when a patient has
multiple seizure foci (eg, bilateral mesial temporal onset) or
when a seizure focus co-localizes with eloquent cortex.47,48
The first multicenter, double-blind, randomized, controlled
trial of 191 patients that assessed RNS efficacy came from
the RNS System Pivotal Trial, which found that patients
who underwent RNS treatment had a significantly higher
seizure reduction than the sham control group.49 Specifi-
cally, seizure reduction was 41.5% and 9.4% for the treat-
ment and sham group, respectively, 5 months after
implantation. Recently published long-term outcome data
indicate that the median seizure reduction increased to
65.7% at approximately 6 years and that the responder rate
was 59.1% (Table 1).50 There were a number of complica-
tions associated with patients in the trial, including memory
impairment endorsed by 8 patients (4.2%).49 However, this
was a subjective endorsement and preimplantation assess-
ment showed that over 50% of patients had preexisting
memory impairment. Depression was reported in 3.1% of
subjects. The rates of serious adverse effects, including
infection (4.2%) and hemorrhage (2.1%), were comparable
to other neurosurgical procedures involving intracranial
hardware implantation,51 and there were no permanent neu-
rological consequences.
RNS effect on cognition
The exact effect of RNS on cognition is still unclear, but
the current literature suggests that it has a positive long-term
effect on cognition (Table 2). Initially, the RNS System
Epilepsy Study Group published some cognitive data along
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with their findings on seizure reduction.49 The patients were
assessed objectively with neuropsychological tests (ie, Rey
Auditory Verbal Learning Test I–V and Brief Visuospatial
Memory Test-Revised) at baseline and the end of the blind
evaluation period, which was 1-2 years postoperatively.
Despite some subjective data of patients endorsing memory
impairment, there were no objective declines in any cogni-
tive metrics, and there were significant improvements in
verbal functioning, visuospatial abilities, and certain aspects
of memory.
Additional objective cognitive data from the RNS System
Pivotal Trial were analyzed and published separately from
the studies focused on seizure reduction.52 The results
showed small but significant beneficial treatment effects on
naming in patients with neocortical seizure onsets, and mod-
est improvements in verbal learning for patients with mesial
temporal seizure onsets. A major limitation of these findings
is that all the data come from the same group of patients in
the RNS System Pivotal Trial. Well-controlled replication
is required to confirm or reject these findings.
RNS effect on mood
The current evidence suggests that RNS does not have
any negative effects on mood, although there is limited
available evidence (Table 3). Meador et al53 published data
from the RNS System Pivotal Trial on quality of life and
mood, showing that there was a significant improvement in
mood for patients undergoing RNS treatment. Specifically,
they tested patients with the BDI-II and POMS at baseline
and at 1 year and 2 years follow-up. There were significant
decreases in BDI-II scores of 15.2% and 17.9% at 1 and
2 years of follow-up, respectively. For POMS scores, there
was an insignificant decrease of 17.1% between baseline
and 1 year but a significant decrease of 20.8% at 2 years.
The authors argue that this is an important finding because
patients with refractory epilepsy are more likely to be suici-
dal than those who can be medically managed. Although the
current evidence is promising, additional research is
required to confirm the results.
Less Invasive Forms of
Neurostimulation
Trigeminal nerve stimulation
Recently, there has been some investigation into the
effects of TNS on refractory epilepsy. TNS involves stimu-
lating the superficial branch of the trigeminal nerve with an
external pulse generator. TNS has been used to treat psychi-
atric disorders, such as TRD.54 TNS has also been shown
recently to reduce seizure frequency. A large double-blind
multicenter randomized, controlled trial of 50 subjects with
partial-onset seizures showed that the responder rate at
18 weeks was 40.5% compared with 15.6% for the control
group.55 However, a later published correction clarified
that, although there was improvement within the active
treatment group alone, there was no significant difference in
effect between the treatment and control groups and evi-
dence of efficacy was therefore insufficient. Subsequently
published long-term data for the study showed that respon-
der rates at 1 year were 36.8% and 25% for the treatment
and control group, respectively.56
There are few studies that directly investigate the effects
of TNS on cognition or mood for patients with refractory
epilepsy. There is some evidence that TNS could be effec-
tive in treating depression. Shiozawa et al57 presented a
study of 11 patients with major depressive disorder and
found that there was a significant reduction in depressive
symptoms after 10 sessions of TNS. However, the limita-
tions were a small sample size, lack of control group, short
follow-up, and the lack of a double-blind study design. In
addition, these patients did not undergo continuous stimula-
tion like those treated for epilepsy.
Repetitive transcranial magnetic stimulation
Repetitive transcranial magnetic stimulation (or rTMS) is
a noninvasive therapy that involves using an electromag-
netic coil to generate magnetic fields that influence electri-
cal activity in targeted brain regions. Evidence for the
efficacy of rTMS for seizure reduction is mixed. A small
blinded randomized-controlled trial showed that seizure
reduction was weak and transient.58 Conversely, another
double-blind randomized, controlled trial showed that
rTMS significantly decreased seizure frequency in patients
with refractory epilepsy and cortical development malfor-
mations.59 However, a limitation of both studies is the small
sample size, which should be considered when interpreting
the results.
There is some evidence that TMS improves cognition in
healthy patients. A study of 15 patients showed that patients
exposed to TMS targeted to either frontal or parietal lobes
prior to testing performed better on cognitive tests than
when they were exposed to a sham treatment.60 Higher
TMS strength was associated with greater improvement in
performance. There is also some evidence that rTMS
improves cognition in patients with refractory epilepsy.
Fregni et al59 also investigated the cognitive effects of
rTMS in their study and found improvement for all their
metrics. They tested patients with 3 cognitive tests at base-
line, immediately after treatment, and 2 weeks afterward.
The treatment group scores were significantly higher than
the control group scores in right-handed simple reaction
time (10.8% vs 1.1%) and Stroop test (17.1% vs 2.7%).
Differences between scores for the other tests were not sig-
nificant.
There is evidence that rTMS has a positive effect on
mood in patients with depression, but it is unclear whether
rTMS has any effect on mood in patients with refractory epi-
lepsy. A double-blind randomized-controlled study of 70
patients showed that rTMS provided short-term improve-
ment in patients with recurrent depression.61 Subjects were
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tested with 2 depression scales, and scores were recorded at
baseline and immediately after undergoing 10 TMS daily
sessions over a 2-week period. Both depression scales
decreased roughly 45% from baseline at the end of treat-
ment. However, there are no studies specifically investigat-
ing whether rTMS influences mood in patients with
refractory epilepsy.
Transcranial direct current stimulation
tDCS is a noninvasive neurostimulation technique that
involves constant, low current delivered to the brain area of
interest via electrodes on the scalp. A prospective random-
ized, controlled trial of 19 patients with refractory epilepsy
showed that tDCS reduced the number of epileptiform dis-
charges when compared to a sham treatment.62 The mean
reduction of epileptiform discharges relative to baseline at
1 month after tDCS was significantly greater for the treat-
ment group than for the control group (64.3% vs 5.8%).
There was also a nonsignificant trend in mean seizure fre-
quency reduction between the 2 groups, with reduction of
seizures in the treatment and control groups of 44.0% and
11.1%, respectively. The limitations of this study include
the short follow-up period (1 month), small sample size,
and subject heterogeneity, which could have affected the
results due to potential outside confounding factors. Other
studies provide more robust seizure reduction results. A ran-
domized-controlled study of 29 patients showed that a sin-
gle treatment of 18 total minutes of tDCS resulted in a
42.1% seizure reduction versus 17.0% reduction for the con-
trol group.63
The effect of tDCS on cognition and mood is unclear. An
abstract of preliminary data described cognitive effects of a
single-blinded randomized, controlled trial where patients
underwent 5 consecutive days of 20-minute tDCS treat-
ments.64 The patients were tested at baseline and subse-
quently after treatment with immediate, 5-minute delay, or
20-minute delay recall tests, as well as a Symbol Digit
Modalities Test and Stroop Color Word Test. There were no
significant treatment-related changes for any metric,
prompting the suggestion that long-term larger studies were
required. Conversely, there is evidence that tDCS has
antidepressive effects. Results of a study where patients
with major depressive disorder underwent tDCS treatment
for 10 sessions over a 2-week period showed a reduction of
40.4% in a standardized depression scale evaluated by a
blinded rater.65 However, there are no studies investigating
the effect of tDCS on mood specifically in patients with
refractory epilepsy.
Study Limitations
There are number of limitations to consider. First,
although there were a number of well-controlled studies
included in this review, many of them had a primary focus
of investigating the effect of neuromodulation on seizure
reduction, rather than cognitive or mood outcomes. There-
fore, evaluating the quality of the studies in terms of possi-
ble confounding variables was challenging because
cognition and mood effect metrics were not the primary out-
come variables. Second, there were no consistent psycho-
metric or cognitive outcome measures across studies that
allowed for between-study comparisons or statistical analy-
sis, highlighting a need for standardization and verification
across studies. Third, a number of studies were single-arm
(ie, without control), which did not allow for proper treat-
ment evaluation, as the treatment group could not be
assessed against a proper control group. Fourth, the most
rigorous form of experimentation is where cognition and
mood are tested between patients who have neuromodula-
tion turned on versus off. Although some studies presented
here did utilize that methodology, most were retrospective
or one-armed case series without control groups. Therefore,
future research should focus on applying the most rigorous
methodologies to provide more reliable evidence. The out-
comes in the literature should be interpreted within the con-
text of the limitations.
Conclusion
Neurostimulation can be an effective seizure-reduction
treatment for patients with refractory epilepsy who are not
candidates for resective surgery. Neurostimulation may
also modulate cognition and mood, although it is chal-
lenging to disentangle primary effects from effects sec-
ondary to seizure reduction. Here we reviewed the current
evidence for how different invasive and noninvasive neu-
rostimulation therapies affect cognition and mood. Inva-
sive techniques are moderately better studied than newer
noninvasive techniques. Overall, current evidence indi-
cates that the neurostimulation therapies reviewed here do
not produce deterioration in cognition or mood, and there
is some evidence that cognition and mood may improve
with some invasive forms of neurostimulation. However,
the available evidence was generally limited to studies
with small sample sizes or methodology susceptible to
confounding. Better designed studies (eg, randomized,
controlled or experimental trials) measuring established,
standardized psychometric parameters are necessary to
fully characterize the effects of neurostimulation on cog-
nition and mood and to elucidate the mechanisms underly-
ing these effects.
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